Equities Analysts Set Expectations for BNTC FY2026 Earnings

Benitec Biopharma Limited (NASDAQ:BNTC) – Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Benitec Biopharma in a research note issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.96) for the year, up from their prior forecast of ($0.97). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.37) EPS and FY2027 earnings at ($1.29) EPS.

Other equities research analysts have also issued research reports about the stock. TD Cowen reissued a “buy” rating on shares of Benitec Biopharma in a report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a report on Monday, April 20th. Evercore began coverage on shares of Benitec Biopharma in a report on Tuesday, May 12th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Benitec Biopharma Stock Up 1.3%

Shares of Benitec Biopharma stock opened at $11.60 on Thursday. The firm has a market cap of $398.46 million, a PE ratio of -10.18 and a beta of 0.28. Benitec Biopharma has a 12-month low of $9.85 and a 12-month high of $17.15. The company’s fifty day simple moving average is $11.74 and its two-hundred day simple moving average is $12.04.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. lifted its position in shares of Benitec Biopharma by 92.0% in the 4th quarter. Simplify Asset Management Inc. now owns 151,163 shares of the biotechnology company’s stock worth $2,036,000 after purchasing an additional 72,438 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Benitec Biopharma in the 4th quarter worth about $111,000. Bank of New York Mellon Corp lifted its position in shares of Benitec Biopharma by 37.6% in the 1st quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 11,877 shares during the period. Truvestments Capital LLC lifted its position in shares of Benitec Biopharma by 156.5% in the 4th quarter. Truvestments Capital LLC now owns 3,834 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,339 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in shares of Benitec Biopharma by 44.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 904 shares during the period. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.